[31] It is important to note that some autoimmune conditions have been flagged as potential hazards for several autoimmune conditions, such as ulcerative colitis and thyroiditis
Trial SURMOUNT-1 Trial Phase 3 multicenter, double-blind, randomized, placebo-controlled trial was conducted at 119 sites in nine countries Intervention Participants were randomly assigned in a 1:1:1:1 ratio to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or placebo, administered subcutaneously once weekly for 72 weeks as an adjunct to lifestyle intervention
Moreover, nod-like receptor protein 3 (NLRP3) inflammasome activation is highly involved in apoptotic cell death (112, 113)
Aim for 7-9 hours of restful sleep each night to support hormonal health and libido
Fiber, protein, gut health, exercise, sleep and stress management all support natural GLP-1 release
Standard practice recommends starting at 0.25 milligrams for four weeks regardless of previous tirzepatide dose